Hydrochlorothiazide/Triamterene

氢氯噻嗪/氨苯蝶啶

Report date: 2022/03/23 10:14:52

Base Information

Drug NameHydrochlorothiazide/Triamterene
Drug Alias Name氨苯蝶啶/氢氯噻嗪hydrochlorothiazide and triamterenetriamterene and hydrochlorothiazideTriamterene/HydrochlorothiazideHydrochlorothiazide - triamterene +[7] 
ClassificationSmall molecules
Mechanisms of ActionThiazide-sensitive sodium-chloride cotransporter inhibitorsSodium channel alpha subunit blockers
TargetsThiazide-sensitive sodium-chloride cotransporterSodium channel alpha subunit
Therapy Area/IndicationsEdemaHypertension
Global Approved IndicationsEdemaHypertension
Approved Indications in ChinaEdemaHypertension
Original Approved Country/TerritoryUnited States
Original Approved Date1965/12/02
Country/TerritoryUnited StatesMainland China
CombinationsYes HydrochlorothiazideTriamterene
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Lisheng Pharmaceutical Co Ltd
Inactive CompaniesGlaxosmithkline Llc
Active IndicationsEdemaHypertension
Inactive IndicationsN/A

Other Information

ATC CodeC03EA01
Related LinksKEGG